These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11545498)

  • 1. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals.
    Ma D; McDevitt MR; Finn RD; Scheinberg DA
    Appl Radiat Isot; 2001 Oct; 55(4):463-70. PubMed ID: 11545498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody therapy of acute myelogenous leukemia.
    Jurcic JG
    Cancer Biother Radiopharm; 2000 Aug; 15(4):319-26. PubMed ID: 11041016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
    Ma D; McDevitt MR; Finn RD; Scheinberg DA
    Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
    Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
    J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
    McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA
    J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
    Zalutsky MR; Bigner DD
    Acta Oncol; 1996; 35(3):373-9. PubMed ID: 8679269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.
    Sgouros G; Ballangrud AM; Jurcic JG; McDevitt MR; Humm JL; Erdi YE; Mehta BM; Finn RD; Larson SM; Scheinberg DA
    J Nucl Med; 1999 Nov; 40(11):1935-46. PubMed ID: 10565792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted alpha-particle immunotherapy for acute myeloid leukemia.
    Jurcic JG; Rosenblat TL
    Am Soc Clin Oncol Educ Book; 2014; ():e126-31. PubMed ID: 24857092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
    Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
    Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
    Jurcic JG
    Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
    Rosenblat TL; McDevitt MR; Mulford DA; Pandit-Taskar N; Divgi CR; Panageas KS; Heaney ML; Chanel S; Morgenstern A; Sgouros G; Larson SM; Scheinberg DA; Jurcic JG
    Clin Cancer Res; 2010 Nov; 16(21):5303-11. PubMed ID: 20858843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
    McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
    Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study.
    Vandenbulcke K; Thierens H; Offner F; Janssens A; de Gelder V; Bacher K; Philippé J; De Vos F; Dierckx R; Apostolidis C; Morgenstern A; Slegers G
    Nucl Med Commun; 2004 Nov; 25(11):1131-6. PubMed ID: 15577593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
    Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
    Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted alpha particle immunotherapy for myeloid leukemia.
    Jurcic JG; Larson SM; Sgouros G; McDevitt MR; Finn RD; Divgi CR; Ballangrud AM; Hamacher KA; Ma D; Humm JL; Brechbiel MW; Molinet R; Scheinberg DA
    Blood; 2002 Aug; 100(4):1233-9. PubMed ID: 12149203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
    Wilbur DS; Hamlin DK; Chyan MK; Brechbiel MW
    Bioconjug Chem; 2008 Jan; 19(1):158-70. PubMed ID: 18072725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation.
    Wulbrand C; Seidl C; Gaertner FC; Bruchertseifer F; Morgenstern A; Essler M; Senekowitsch-Schmidtke R
    PLoS One; 2013; 8(5):e64730. PubMed ID: 23724085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.